Similarly, compared to perioperative chemotherapy (82), combining anti-CTLA-4 (tremelimumab) and anti-PD-L1 (durvalumab) did not significantly prolong median relapse-free survival (9.7 months) and overall survival (24.5 months) in pMMR CRC patients with liver metastasis (36). This evidence concerns the gene CTLA4 and colorectal carcinoma.